Gland Pharma Q4 FY26 profit jumps 97%, sales up 22%

Stock jumps after Q4 numbers

Gland Pharma shares jumped 12.37% to Rs 2,098.05 after the company reported a sharp rise in consolidated profit for Q4 FY26. The move came after the Hyderabad-based drug maker posted higher sales and stronger operating profitability. The stock reaction stood out against a weak broader market on one of the tracked sessions. At 12:49 IST, the stock was quoted at Rs 1,913.1 on the NSE, up 2.27% on the day. In the same snapshot, the NIFTY was down around 0.64% at 24,170.45 and the Sensex was down 0.72% at 77,285.81.

Q4 FY26: profit nearly doubles on higher sales

For Q4 FY26, Gland Pharma reported a 96.62% year-on-year increase in consolidated net profit to Rs 366.7 crore. Consolidated net sales rose 22.31% year-on-year to Rs 1,742.80 crore. Profit before tax (PBT) stood at Rs 505.79 crore, up 75.42% from Rs 288.33 crore in Q4 FY25. The quarter’s results indicate a combination of revenue growth and improved cost and product mix. The company also reported a stronger operating performance at the EBITDA level.

EBITDA rises; margin reported at 29%

Consolidated EBITDA for Q4 (March 2026 quarter) stood at Rs 513 crore, up 48% year-on-year. The company reported an EBITDA margin of 29% for the quarter. These operating metrics were highlighted alongside the sharp rise in net profit. Management commentary during FY26 also referred to an adjusted EBITDA margin, which provides additional context on underlying profitability.

Geography mix: US remains the largest contributor

Gland Pharma’s Q4 FY26 revenue split showed the US as the largest market. Revenue from the US aggregated to Rs 980.7 crore, up 25.44% year-on-year. Europe revenue added up to Rs 381.4 crore, up 36% year-on-year. Revenue from the rest of the world was Rs 254.9 crore, up 6% year-on-year.

Smaller markets: mixed performance

In regulated markets outside the US and Europe, sales in Canada, Australia and New Zealand were Rs 58.8 crore, down 2% year-on-year. India sales were Rs 67 crore, up 28% year-on-year. The figures underline how the company’s quarterly growth was led primarily by the US and Europe, while some smaller markets were softer.

FY26 full-year: double-digit revenue growth

For the full year ended March 2026, consolidated net profit rose 47.07% to Rs 1,027.32 crore, compared with Rs 698.53 crore in the year ended March 2025. Sales rose 14.50% to Rs 6,430.65 crore from Rs 5,616.50 crore in the previous year. Management linked the year’s performance to progress across the business, including Cenexi. The company cited consolidated revenue growth of 14.5% for FY26 and an adjusted EBITDA margin of 26%.

Product launches and filings: focus on the US

During the Q4 quarter, the company launched five molecules in the US, including Dalbavancin and Brimonidine. This took total US launches in FY26 to 31 products, as per the update. Earlier in FY26, the company also reported a strong cadence of launches and filings in the US, reflecting its focus on regulated markets. Such launches are closely tracked by investors in injectables and complex generics, where timing and approvals can affect quarterly revenue visibility.

What management said: base business, CDMO and cost efficiency

Executive Chairman Srinivas Sadu said the FY26 performance, with consolidated revenue growth of 14.5% and adjusted EBITDA margin of 26%, reflected progress across businesses including Cenexi. He also stated that the 38% adjusted EBITDA margin of the base business was supported by robust growth in the CDMO segment. The commentary pointed to new product launches and improved profitability in the existing portfolio. Cost-efficiency initiatives were cited as another driver of profitability improvements. Management also said it remains confident about sustaining momentum, supported by a pipeline of complex product launches and continued ramp-up of CDMO partnerships.

Earlier quarter context: Q3 FY26 momentum and trading action

In Q3 FY26, the company reported a 27.7% increase in consolidated net profit to Rs 261.48 crore on a 22.5% rise in net sales to Rs 1,695.36 crore compared with Q3 FY25. The stock had reacted strongly to the Q3 update, with shares surging as much as 9.32% to an intraday high of Rs 1,847.10 on the NSE, while the BSE saw an intraday high of Rs 1,849 in one session. The company’s Q3 operational performance included EBITDA of about Rs 435 crore and an EBITDA margin around 25.65%, according to the cited figures. R&D spending for that quarter was reported at Rs 65 crore versus Rs 44 crore in the corresponding period last year. In the same Q3 context, the company launched nine molecules in the US and filed nine ANDAs, with four approvals taking the cumulative total to 384 ANDA filings in the US.

Key numbers snapshot

Market impact: what investors are likely to track

The immediate market response to the Q4 print reflected the scale of profit growth and the reported improvement in operating profitability. The geographic breakup highlighted that the US and Europe delivered the strongest year-on-year growth in Q4 FY26, with India also showing a healthy increase from a smaller base. For a company with meaningful exposure to regulated markets, investors typically monitor the pace of launches, ANDA approvals, and sustainability of margins. Management’s emphasis on CDMO growth, cost efficiency, and the base business margin provides context for how the company is thinking about profitability levers. Separately, the stock has shown mixed moves across sessions, including a reported close down 1.80% at Rs 1,861 on the BSE in one session, indicating that sentiment can shift with broader market conditions and near-term expectations.

Conclusion

Gland Pharma’s Q4 FY26 results combined strong profit growth with double-digit sales expansion and higher EBITDA. The quarter was supported by growth in the US and Europe, along with management’s focus on CDMO and cost-efficiency initiatives. For FY26, the company reported higher full-year sales and profit, alongside an adjusted EBITDA margin of 26%. Near-term attention is likely to stay on execution in complex launches, the pace of US product additions, and the ramp-up of CDMO partnerships referenced by management.